Equities

Zhejiang Shapuaisi Pharmaceutical Co Ltd

603168:SHH

Zhejiang Shapuaisi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.10
  • Today's Change-0.150 / -2.40%
  • Shares traded4.43m
  • 1 Year change-33.70%
  • Beta1.0477
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments369554244
Total Receivables, Net668457
Total Inventory845961
Prepaid expenses333031
Other current assets, total----161
Total current assets553728554
Property, plant & equipment, net834668528
Goodwill, net365327336
Intangibles, net181160166
Long term investments23269--
Note receivable - long term------
Other long term assets------
Total assets2,1701,9581,585
LIABILITIES
Accounts payable1238126
Accrued expenses565874
Notes payable/short-term debt8600
Current portion long-term debt/capital leases195.93--
Other current liabilities, total836195
Total current liabilities368206195
Total long term debt713438
Total debt1764038
Deferred income tax--1.42--
Minority interest9.7010--
Other liabilities, total2.47----
Total liabilities451251233
SHAREHOLDERS EQUITY
Common stock379373323
Additional paid-in capital913889631
Retained earnings (accumulated deficit)456445399
Treasury stock - common(28)----
Unrealized gain (loss)------
Other equity, total------
Total equity1,7201,7071,352
Total liabilities & shareholders' equity2,1701,9581,585
Total common shares outstanding373373323
Treasury shares - common primary issue6.5500
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.